Coagulation and fibrinolytic studies in women receiving an anovulatory drug (medroxyprogesterone acetate with estradiol)

Abstract In 16 women receiving Provest who were subjected to a controlled study of clinical manifestations and laboratory assays of coagulation and fibrinolytic components: 1. 1. Significant differences in blood coagulation and fibrinolytic components throughout treated and untreated menstrual cycles in 8 patients were not detected. 2. 2. Medroxyprogesterone with ethinyl estradiol was an effective oral contraceptive. 3. 3. Side effects, with the possible exception of breakthrough bleeding, were minor. No evidence of thrombotic phenomena or masculinization was found.